Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zevra TherapeuticsSTU:1GDA +0.82%69 Current Ratio is 5.17 as of Jun. 2026, which is 3% above its 10-year median of 5.03. GuruFocus rates STU:1GDA with a GF Score™ of 69/100 and a GF Value™ of €17.92 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 1,409 Biotechnology companies, Zevra Therapeutics ranks better than 59.62% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Zevra Therapeutics's current ratio for the quarter that ended in Jun. 2026 was 5.17.
Zevra Therapeutics has a current ratio of 5.17. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Zevra Therapeutics's Current Ratio or its related term are showing as below:
STU:1GDA'
s Current Ratio Range Over the Past 10 Years
Min: 0.07 Med: 5.03 Max: 36.41
Current: 5.17
During the past 13 years, Zevra Therapeutics's highest Current Ratio was 36.41. The lowest was 0.07. And the median was 5.03.
STU:1GDA's Current Ratio is ranked better than 59.62% of 1409
companies
in the Biotechnology industry
Industry Median: 3.85
vs STU:1GDA: 5.17
Zevra Therapeutics (STU:1GDA) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Zevra Therapeutics Current Ratio Related Terms
Zevra Therapeutics Current Ratio Historical Data
* Premium members only.
The historical data trend for Zevra Therapeutics's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:1GDA vs TECX, RLMD, ALT: Current Ratio Comparison
For the Biotechnology subindustry, Zevra Therapeutics's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zevra Therapeutics Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zevra Therapeutics's Current Ratio distribution charts can be found below:
* The bar in red indicates where Zevra Therapeutics's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zevra Therapeutics (STU:1GDA) has a Current Ratio of 5.17 as of Jun. 2026. This is near median its historical median of 5.03. Over the past decade, Zevra Therapeutics' Current Ratio has ranged from 0.07 to 36.41. According to the industry distribution chart, Zevra Therapeutics ranks #569 out of 1409 companies in the Biotechnology industry, placing it in the top 40.4%.
Is Zevra Therapeutics' Current Ratio too high?
Zevra Therapeutics' current Current Ratio of 5.17 is near median its 10-year median of 5.03. Over the past 10 years, this metric has ranged from a low of 0.07 to a high of 36.41. The Biotechnology industry median Current Ratio is 3.85. Zevra Therapeutics' value of 5.17 is 34.3% above this industry median. Based on the distribution chart, Zevra Therapeutics ranks #569 out of 1409 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Zevra Therapeutics has a GF Score™ of 69/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Zevra Therapeutics' Current Ratio compare to TECX and RLMD?
According to the Biotechnology industry distribution chart, Zevra Therapeutics ranks #569 out of 1409 companies for Current Ratio. This puts Zevra Therapeutics in the upper half of its industry. The industry median Current Ratio is 3.85. Zevra Therapeutics' value of 5.17 is 34.3% above this benchmark. Historically, Zevra Therapeutics' own Current Ratio has ranged from 0.07 to 36.41 over the past decade. While the company's 10-year median is 5.03 vs. the industry median of 3.85, Zevra Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.85, based on 1,409 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zevra Therapeutics's current Current Ratio of 5.17 is 34.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zevra Therapeutics's current Current Ratio is 5.17, which is near median its own 10-year median of 5.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zevra Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Zevra Therapeutics (STU:1GDA) is currently considered Possible Value Trap. The stock's GF Value™ is €17.92, compared to a current price of €9.80 — trading 45.3% below its estimated fair value. The current Current Ratio is 5.17, which is near median its 10-year median of 5.03 and 34.3% above the Biotechnology industry median of 3.85. Zevra Therapeutics' overall GF Score™ is 69/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Zevra Therapeutics (STU:1GDA), the current Current Ratio is 5.17 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zevra Therapeutics (STU:1GDA) Overvalued in 2026?
Based on GuruFocus' analysis, Zevra Therapeutics stock appears to be undervalued.
The current stock price of €9.80 is trading 45.3% below its estimated GF Value™ of €17.92.
GuruFocus considers Zevra Therapeutics to be Possible Value Trap.
Key valuation signals for STU:1GDA:
Current Ratio: 5.17 (near median its 10-year median of 5.03)
GF Value™: €17.92 vs. price of €9.80 (45.3% below fair value)
Industry Position: 34.3% above the Biotechnology median (#569 of 1409)
No single metric tells the full story. See the STU:1GDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.
69GF Score
Get the complete analysis for STU:1GDA
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:1GDA has been successfully added to your 
